ADAFOSBUVIR, адафосбувир , أدافوسبوفير ,

New Drug Approvals

ADAFOSBUVIR

AL335; ALS-335; JNJ-64146212 , D11364

адафосбувир [Russian] [INN]

أدافوسبوفير [Arabic] [INN]

Propan-2-yl N-((P5’S)-4′-fluoro-2′-C-methyl-p-o-phenyl- 5′-uridylyl)-L-alaninate

propan-2-yl (2S)-2-{[(S)-{[(2S,3S,4R,5R)-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-2-fluoro-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy}(phenoxy)phosphoryl]amino}propanoate

Isopropyl (2S)-2-{[(S)-{[(2S,3S,4R,5R)-5-(2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl)-2-fluoro-3,4-dihydroxy-4-methyltetrahydro-2-furanyl]methoxy}(phenoxy)phosphoryl]amino}propanoate (non-preferred name

Propan-2-yl N-((P5’S)-4′-fluoro-2′-C-methyl-p-o-phenyl- 5′-uridylyl)-L-alaninate

545.5 g/mol, C₂₂H₂₉FN₃O₁₀P

CAS Registry Number 1613589-09-5

Adafosbuvir is under investigation in clinical trial NCT02894905 (A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of AL-335).

• Originator Alios BioPharma
• Developer Alios BioPharma; Janssen
• Class Antivirals; Pyrimidine nucleotides; Uracil nucleotides
• Mechanism of Action Hepatitis C virus NS 5 protein inhibitors

• Phase II Hepatitis C

• 28 Oct 2019 No recent reports of development identified for phase-I development in Hepatitis-C(In volunteers) in USA (PO)
• 28 Sep 2018 No recent reports of development identified for phase-I development in Hepatitis-C in France (PO)
• 28 Sep 2018 No recent reports of development identified for phase-I development in Hepatitis-C in Georgia (PO)

Adafosbuvir (AL 335), a monophosphate prodrug…

View original post 1,286 more words

Advertisement